- Monday, September 2, 2024 @ 12:00 am
Amphilix AG, a drug discovery company using a proprietary linker platform to enhance the properties of multifunctional molecules and the Center for Radiopharmaceutical Sciences at the Paul Scherrer Institute (PSI, Villigen, Switzerland) have entered into a collaboration to develop a new, differentiated radioligand therapy approach for cancer.
Radioligand therapy, where radiation is targeted specifically to cancer cells using a small ligand conjugated to a radioactive payload to cause cell death, is a burgeoning field of nuclear medicine. Amphilix and Dr. Martin Behes Group at the PSI previously demonstrated selective tumour uptake of a new radioligand that is differentiated from existing products. In particular, the novel therapeutic approach aims to extend the scope of radioligand therapies into new cancer indications. The collaboration with the continued support of Innosuisse, the Swiss Innovation Agency will continue to optimize the molecule and advance the product towards clinical application.
Guido Koch CEO of Amphilix welcomes the continuation of the collaboration : ‘I’m excited to collaborate with world leading experts in the field to develop next generation targeted radiotherapeutics with a meaningful impact for patients’.
Martin Behe, Group Leader at PSI is looking forward to further develop this new approach: "Our collaboration to date has shown that the combination of Amphilix technology with PSIs know how and expertise in the successful development of novel radioligands has the potential to develop new therapies - ultimately benefiting many patients.”
